azetidine;1H-benzimidazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: azetidine;1H-benzimidazole
• 化学式: C10H13N3
• 分子量: 175.23
• InChiKey: ARCQYYRRCUIDLF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.54
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  40.7
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• [EN] COMPOSITIONS AND METHODS FOR PREPARING AND USING AZETIDINES<br/>[FR] COMPOSITIONS ET PROCÉDÉS DE PRÉPARATION ET D'UTILISATION D'AZÉTIDINES
  申请人：UNIV VIRGINIA PATENT FOUNDATION

  公开号：WO2019204740A1

  公开（公告）日：2019-10-24

  The present disclosure provides azetidine compounds of Formula I and their pharmaceutically acceptable salts, their compositions, and methods for their use in determining azetidine compound binding to proteins. The azetidine compounds are useful as probes, for monitoring diacylglycerol kinase activity, and for identifying druggable targets.

  本公开提供了Formula I的氮杂环化合物及其药用盐，它们的组合物，以及它们在确定氮杂环化合物与蛋白质结合方面的使用方法。这些氮杂环化合物可用作探针，用于监测二酰基甘油激酶活性，并用于识别可药用的靶标。
• COMPOSITIONS AND METHODS FOR PREPARING AND USING AZETIDINES
  申请人：University of Virginia Patent Foundation

  公开号：US20210101884A1

  公开（公告）日：2021-04-08

  The present disclosure provides azetidine compounds of Formula I and their pharmaceutically acceptable salts, their compositions, and methods for their use in determining azetidine compound binding to proteins. The azetidine compounds are useful as probes, for monitoring diacylglycerol kinase activity, and for identifying druggable targets.
• [EN] AZETIDINE BENZIMIDAZOLES AS PDE10 INHIBITORS<br/>[FR] AZÉTIDINE BENZIMIDAZOLES UTILISABLES EN TANT QU'INHIBITEURS DE PDE10
  申请人：MERCK SHARP & DOHME

  公开号：WO2014078214A1

  公开（公告）日：2014-05-22

  The present invention is directed to substituted azetidine benzimidazole compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.